Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04757792 Completed - COVID-19 Disease Clinical Trials

Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU

Start date: June 6, 2020
Phase:
Study type: Observational

Retrospective multicenter study to evaluate the data of COVID-19 patients who were admitted to university hospitals in relation to their recent administration or maintenance on non-steroidal anti-inflammatory drugs (NSAID) prior to have COVID-19 disease and to analyze it in relation to outcome of these patients.

NCT ID: NCT04757298 Completed - COVID-19 Testing Clinical Trials

Optimization of a New Adaptive Intervention to Increase COVID-19 Testing

Start date: February 12, 2021
Phase: N/A
Study type: Interventional

This study tests an adaptation of the HIV Continuum of Prevention, Care, and Treatment Framework (CoPCT) for use in tracking COVID-19 testing and follow-up in a medically and socially vulnerable population. This study uses an integrated research collaborative framework that facilitates dialogue among researchers, community members, and service providers as a tool for optimizing the adaptive intervention and will take place at the North Jersey Community Research Initiative (NJCRI)

NCT ID: NCT04757272 Completed - Clinical trials for Corona Virus Infection

Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?

Start date: May 1, 2020
Phase:
Study type: Observational

Modulation of the renin angiotensin system by the chronic hepatitis C virus treatment either by (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon) protocols could give an explanation for the low incidence of COVID-19 among Egyptian population. Adding it may play a role in COVID 19 prophylaxis.

NCT ID: NCT04757207 Completed - Covid19 Clinical Trials

Pandemia And Exercise in Turkey in University Students of Turkey

Start date: February 22, 2021
Phase:
Study type: Observational

The aim of this study is to determine to what extent university students' physical activities are affected by staying at home during the pandemia.

NCT ID: NCT04756869 Completed - Covid19 Clinical Trials

Monitoring Health Care Workers at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology

Start date: April 28, 2020
Phase:
Study type: Observational

This prospective study of health care workers utilizes wearable sensors, surveys and symptom logs, and biospecimens in an effort to improve self-monitoring practices for COVID-19 among health care workers and to provide key data for the development of a predictive model for early detection of COVID-19 infection.

NCT ID: NCT04756830 Active, not recruiting - COVID-19 Clinical Trials

A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19

Start date: February 19, 2021
Phase: Phase 4
Study type: Interventional

This is an open-label uncontrolled study in which all participants will receive two doses of the inactivated adsorbed vaccine against COVID-19, and will be followed up for safety and immunogenicity analysis for 24 months.

NCT ID: NCT04756674 Withdrawn - Covid19 Clinical Trials

The Impact of Covid-19 on Skeletal Muscle

Start date: March 10, 2021
Phase:
Study type: Observational

With the recent worldwide outbreak of the COVID-19 infection and the huge impact it has had upon lives in the UK, it is key to increase knowledge on the impact of the virus on the body. Certain aspects of the virus' characteristics are also poorly understood: The reason behind the variation in response between individuals, and the long-term impacts of infection upon the body. It is already known from previous research that muscle-health plays an important role in health, with other illnesses known to have an impact upon muscle health. A large number of studies have investigated the relationship between muscle and health, with an increasing focus upon the impact upon the mitochondria within the muscle cells. Mitochondria are the energy-producing component of a cell and are vital not just for the muscle-cells but for the body as a whole. The researchers hope that by investigating the impact of COVID-19 infection upon human skeletal muscle, the question of why individuals have different responses to the infection and the mechanism of the longer-term impact of infection can be answered. This added knowledge will then, hopefully, be able to guide therapy targets in the future.

NCT ID: NCT04756518 Completed - COVID-19 Clinical Trials

COVID-19 Infection and Machine Learning Using Artificial Intelligence (AI)

Start date: July 6, 2020
Phase:
Study type: Observational

COVID-19 infection is currently confirmed by a complex, multiple-step procedure starting with a mucosal swab, followed by viral RNA extraction and processing and qPCR. This study aims to explore a novel method using machine learning and artificial intelligence (AI) algorithm to diagnose COVID-19 infection through the morphological analysis of lymphocyte subset in the peripheral blood. This study will also risk stratify patients with COVID 19 infection based on the above finding along with other clinical, haematological and biochemical parameters with a view to predict clinical outcome with high sensitivity and specificity.

NCT ID: NCT04756479 Completed - Covid19 Clinical Trials

Mortality Due to COVID-19 in the COVID-AGEBRU Study

COVID-AGEBRU
Start date: March 1, 2020
Phase:
Study type: Observational

The COVID-Age Brugmann study aims to identify the clinical predictors of mortality risk in older patients admitted to an acute care unit due to COVID-19

NCT ID: NCT04756323 Active, not recruiting - COVID-19 Clinical Trials

A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)

Start date: October 27, 2020
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.